COVID-19, SARS-CoV 2
Conditions
Keywords
Favipiravir, hydroxychloroquine, COVID-19
Brief summary
Hydroxychloroquine is widely used to treat autoimmune diseases. Clinical investigation has found that a high concentration of cytokines were detected in the plasma of critically ill patients infected with SARS-CoV-2, therefore, hydroxychloroquine as anti-inflammatory agents may reduce this response in accord with their use in autoimmune disease where the cytokine response can be reduced. Favipiravir is an antiviral drug developed in Japan that the data sheet notes that it is a pyrazinecarboxamide derivative with activity against influenza viruses, west nile virus, yellow fever virus, foot and mouth disease virus as well as against flaviviruses, arenaviruses, bunyaviruses and alphaviruses. In February the drug was used for COVID-19 disease in China and was declared effective in treatment, and a report published (in press) comparing Favipiravir with Lopinavir /ritonavir suggested that Favipiravir was superior for prevention of disease progression and viral clearance. The objective of this pilot study is to compare three arms: hydroxychloroquine; favipiravir; standard care (no specific SARS-CoV-2 treatment) only, in symptomatic patients infected by SARS-CoV-2 in an open label randomized clinical trial. The difference between groups will allow an effect size to be determined for a definitive clinical trial.
Detailed description
Coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2/2019-nCoV) and has developed into a pandemic with serious global public health and economic sequelae. As of June 30, 2020 over 10,000,000 cases have been confirmed worldwide leading to over 500,000 deaths (https://coronavirus.jhu.edu/map.html). Currently no vaccine exists, however chloroquine and hydroxychloroquine have been documented as potentially having antiviral properties with efficacy against COVID-19 disease. Chloroquine is used in the treatment of malaria and amebiasis and is still used in the prophylaxis of malaria. Hydroxychloroquine sulfate is a derivative of Chloroquine that has been demonstrated to be much less (\ 40%) toxic than Chloroquine in animals. Hydroxychloroquine is widely used to treat autoimmune diseases, due to its immunomodulatory properties, such as systemic lupus erythematosus and rheumatoid arthritis, with an excellent safety profile. In vitro studies have suggested that their mode of action in COVID-19 disease is blockade of SARS-CoV-2 transport from endosomes to endolysosomes, which appears to be a requirement to release the viral genome. Clinical investigation has found that high concentrations of cytokines are detectable in the plasma of critically ill patients infected with SARS-CoV-2, suggesting that cytokine storm is associated with disease severity; therefore, Chloroquine/ hydroxychloroquine may reduce this response by acting as anti-inflammatory agents in accord with their use in autoimmune disease, where their reduction in cytokine response has been extensively researched and demonstrated. Favipiravir is an antiviral drug developed in Japan (as noted in the data sheets) that it is a pyrazinecarboxamide derivative with activity against influenza viruses, west nile virus, yellow fever virus, foot and mouth disease virus as well as against flaviviruses (i.e. arenaviruses, bunyaviruses and alphaviruses). Its mode of action is through inhibition of viral RNA-dependent RNA polymerase. In February the drug was used for COVID-19 disease in China and was declared effective in treatment, and a report published (in press) comparing Favipiravir with Lopinavir /ritonavir suggested that Favipiravir was superior for prevention of disease progression and viral clearance. The Solidarity Trial is a global pragmatic clinical trial being undertaken by WHO that aims to explore the efficacy of different treatment modalities for SARS-CoV-2. An application for Bahrain to join the study for collaboration has been made. In The Solidarity Study there will be four treatment modalities investigated, including chloroquine phosphate alone, remdesivir, lopinarvir with ritonavir or lopinarvir with ritonavir plus interferon. Favipiravir is not included, and therefore this study will not be replicating features of The Solidarity Trial but instead will provide additional and novel findings on favipiravir efficacy.
Interventions
DRUGHydroxychloroquine
400mg BID PO day 1 then 200mg BID PO from day 2 to day 10. In addition to Hydroxychloroquine all patients will receive the standard care (according to local Bahrain COVID19 guidelines). Any patient who is fit for discharge, can be discharged and medications will be stopped on discharge.
DRUGFavipiravir
1600mg BID PO day 1600mg BID PO day 2 to day 10. In addition to Favipiravir all patients will receive the standard care (according to local Bahrain COVID19 guidelines). Any patient who is fit for discharge, can be discharged and medications will be stopped on discharge.
Supportive care according to local guidelines
Sponsors
Ebrahim Khalil Kanoo Community Medical Center
Hereditary blood Disorder Centre - Salmaniya Medical Complex
Mohammed Bin Khalifa Bin Sulman Al Khalifa Cardiac Centre, Awali
Jidhafs COVID-19 Centre
Sitra FICU
Salmaniya Medical Complex- 6th Floor
Salmaniya Medical Complex- Helipad
Royal College of Surgeons in Ireland - Medical University of Bahrain
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
This is a parallel, prospective, interventional and randomized open label pilot trial involving 150 patients with COVID-19 disease. On confirmation of SARS-CoV-2 infection subjects will be randomised to hydroxychloroquine or favipiravir or standard clinical care.
Eligibility
Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Admitted COVID-19 patients being treated as an in-patient at a hospital facility. * COVID-19 diagnosis confirmed by PCR nasopharyngeal swab. * Study participants must be symptomatic with any COVID-19 symptoms defined by the Bahrain National Protocol * Onset of symptoms must be within 10 days prior to enrolment. * Study participants must have the ability to give informed consent. * Participants must be at minimum 21 years of age. * Mild to Moderate COVID-19 disease defined as saturation equals to or more than 93% on room air or PaO2:FiO2 ratio more than 300 on enrolment.
Exclusion criteria
* Severe COVID-19 disease: defined as presence of SpO₂ less than 93% on room air or a PaO₂ to FiO₂ ratio of 300 or lower. * Patients on ventilatory support. * Cardiac dysfunction that would preclude treatment with hydroxychloroquine: 1. Patients on medication known to prolong QT segment. 2. Known history of LQT syndrome. 3. Acquired QT prolongation at baseline \>500ms. 4. AV block. 5. Bundle Branch Block. 6. Known history of Cardiomyopathy, Pulmonary Hypertension, or Sick Sinus Syndrome. 7. History of ventricular tachyarrhythmia. 8. Patients with implantable cardioverter-defibrillator (ICD). 9. Patients with a baseline bradycardia of less than 50 beats per minute. * Renal dysfunction (estimated glomerular filtration rate less than 30ml/min). * Hepatic dysfunction defined as: 1. Transaminitis more than three times the upper limit of normal or 2. Chronic liver disease of Child Pugh Class B or higher. * Gout or a history of gout * Patients that are pregnant or breastfeeding. * Patients with a known allergy to an intervention medication. * Patients who receive any of the study medications prior to randomization * Patient with G6PD * Readmission due to COVID19 disease. * Participants in any other COVID-19 disease trial. * Patients on immunosuppressants, HIV patients, cancer patients who received chemotherapy within the past 6 months, or who are on chronic oral steroids. * Patients unable to give informed consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Primary outcome is the Medial clinical scale at end of study follow up | Until discharge, death or for a maximum of 30 days or readmission | Median clinical scale at end of study follow up (day 14 or on discharge/death, whichever is earlier) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Adverse effects(cardiac, renal, hepatic, hypoglycaemia (defined as RBS <3.9 mmol/L)) | Until discharge,death or for a maximum of 14 days or readmission | Monitor and document all adverse effects during therapy |
| Requirement of ICU Admission | Until discharge, death or for a maximum of 14 days or readmission | Deterioration of clinical condition requiring ICU admission |
| Mortality rate | Mortality will be collected up to 30 days | 30 days Mortality rate due to COVID-19 |
| Readmission rate | Readmission will be collected up to 30 days from start of the study | 30 days readmission rate will be captured |
| Daily National Early Warning (NEWS) 2 Score | Until discharge, death or for a maximum of 14 days | Daily NEWS 2 will be calculated which is a tool that improves the detection and response to clinical deterioration in adult patients and is a key element of patient safety and improving patient outcomes |
| Requirement of Escalation of Respiratory Support | Until discharge, death or for a maximum of 14 days or readmission | Implementation of escalation of Respiratory Support |
| Change in Laboratory indices | Until discharge, death or for a maximum of 14 days | Determination of the change in D-dimer, ratio of Lymphocyte to Neutrophil, lactate before and after treatments as a measure of disease activity |
| Discharge and Length of Hospital Stay | Until discharge, death or for a maximum of 14 days | Patients will be followed during their hospital stay until discharge |
| QT prolongation | Until discharge, death or for a maximum of 14 days or readmission | Determination of the change in QT prolongation, before and after treatments as a measure of disease activity |
| Cardiac arrythmia (fatal and non fatal) | Until discharge, death or for a maximum of 14 days or readmission | Detection of Cardiac arrythmia (fatal and non fatal), before and after treatments as a measure of disease activity |
| Viral clearance | until discharge, death or for a maximum of 30 days | Viral clearance defined as a single negative SARS-CoV2 PCR nasopharyngeal swab |
| Daily Sequential Organ Failure Assessment (SOFA) score | Until discharge, death or for a maximum of 14 days | Daily SOFA score will be calculated which can identify the critical point at which patients exhibit the highest degree of organ dysfunction |
Countries
Bahrain
Outcome results
None listed